CytomX Therapeutics (CTMX) Net Margin (2016 - 2025)
CytomX Therapeutics' Net Margin history spans 12 years, with the latest figure at 3998.49% for Q4 2025.
- For Q4 2025, Net Margin fell 404804.0% year-over-year to 3998.49%; the TTM value through Dec 2025 reached 22.79%, down 4587.0%, while the annual FY2025 figure was 26.73%, 4981.0% down from the prior year.
- Net Margin reached 3998.49% in Q4 2025 per CTMX's latest filing, down from 238.62% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 49.55% in Q4 2024 to a low of 3998.49% in Q4 2025.
- Average Net Margin over 5 years is 312.4%, with a median of 34.81% recorded in 2022.
- Peak YoY movement for Net Margin: surged 33968bps in 2023, then tumbled -404804bps in 2025.
- A 5-year view of Net Margin shows it stood at 312.82% in 2021, then surged by 86bps to 43.61% in 2022, then skyrocketed by 107bps to 3.15% in 2023, then surged by 1475bps to 49.55% in 2024, then tumbled by -8169bps to 3998.49% in 2025.
- Per Business Quant, the three most recent readings for CTMX's Net Margin are 3998.49% (Q4 2025), 238.62% (Q3 2025), and 0.83% (Q2 2025).